Most people are into lists and I am no exception. So, without further ado, here is a list of the top 20 drugs by 2007 sales.
Also, because I’m a nice guy, I’ve published the top 82 compounds with loads of other information that wouldn’t fit in the post (e.g.; 2005 and 2006 sales, CAGR growth rates, 2006 rank, generic name and companies booking sales) here on a larger, non-pharmababble styled page.
I can’t promise all the numbers are flawlessly correct, so you might want to double check them before using them in something of uber-importance. Enjoy.
| Sales (mm) | ||||
| Rank | Brand | 2006 | 2007 | % |
| 1 | Lipitor | $14,385 | $12,700 | -12% |
| 2 | Plavix | $6,057 | $7,977 | 32% |
| 3 | Advair | $6,129 | $7,004 | 14% |
| 4 | Enbrel | $4,379 | $5,375 | 23% |
| 5 | Nexium | $5,182 | $5,216 | 1% |
| 6 | Diovan | $4,223 | $5,012 | 19% |
| 7 | Remicade | $4,428 | $4,975 | 12% |
| 8 | Zyprexa | $4,364 | $4,760 | 9% |
| 9 | Risperdal | $4,183 | $4,696 | 12% |
| 10 | Rituxan | $3,861 | $4,600 | 19% |
| 11 | Singulair | $3,579 | $4,300 | 20% |
| 12 | Herceptin | $3,134 | $4,050 | 29% |
| 13 | Seroquel | $3,560 | $4,027 | 13% |
| 14 | Lovenox | $3,210 | $4,000 | 25% |
| 15 | Effexor | $3,722 | $3,794 | 2% |
| 16 | Aranesp | $4,121 | $3,614 | -12% |
| 17 | Norvasc | $4,866 | $3,510 | -28% |
| 18 | Avastin | $2,364 | $3,425 | 45% |
| 19 | Cozaar | $3,163 | $3,400 | 7% |
| 20 | Atacand | $2,889 | $3,222 | 12% |
Theoretically Related Posts
This post was constructed by .
Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.
If one were so inclined, one could follow him at any of these fine web 2.0 establishments:
Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.
Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.
If one were so inclined, one could follow him at any of these fine web 2.0 establishments:
Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.
Add New Comment
Viewing 2 Comments
Thanks. Your comment is awaiting approval by a moderator.
Do you already have an account? Log in and claim this comment.
Do you already have an account? Log in and claim this comment.
Do you already have an account? Log in and claim this comment.
Add New Comment
Trackbacks
(Trackback URL)